TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival October 25, 2013
TCL Archive Scientists should lobby Congress to support the project, Broad Institute Director Eric Lander says. March 18, 2005
